Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).

Koen AL. et al, (2023), Vaccine

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Yin Z. et al, (2023), Cell Rep, 42

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), J Infect

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect

ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice.

Foster WS. et al, (2023), Immunol Cell Biol

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.

Saunders JE. et al, (2023), EBioMedicine, 90

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A. et al, (2023), Cell Rep, 42

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.

Vatzia E. et al, (2023), NPJ Vaccines, 8

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster

Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.

Voysey M. et al, (2023), Clin Exp Immunol

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.

McMahon WC. et al, (2023), AIDS, 37, 105 - 112

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.

van Doremalen N. et al, (2022), NPJ Vaccines, 7

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Huo J. et al, (2022), Cell Rep

Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.

Nyagwange J. et al, (2022), Int J Infect Dis

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell Discov, 8

Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.

Foster WS. et al, (2022), Cell Rep Med

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Madhi SA. et al, (2022), Lancet Infect Dis

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2022), Nat Med

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Madhavan M. et al, (2022), EBioMedicine

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?